The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.
The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market.
However, high cost related of the stem cell therapy limits the growth of the market.
Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.
This raises the importance of creating public awareness about stem cell research and its clinical potential.
The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues.
Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.
There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US -Food and Drug Administration) approval for clinical usage.
For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis.
Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia.
Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period.
Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.
The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.
Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.
The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.
Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.
The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Stem Cell Therapy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global Stem Cell Therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Pharmicell Co., Inc.
BioTime Inc. (Lineage Cell Therapeutics, Inc.)
Holostem Terapie Avanzate
U.S. Stem Cell, Inc.
Caladrius Biosciences, Inc.
For more information, visit www.researchandmarkets.com